Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany.
The Cardiac Insufficiency Bisoprolol Study (CIBIS) demonstrates that, for patients with heart failure of different aetiologies, administration of the beta 1-adrenoceptor blocker bisoprolol as an adjuvant to the standard therapy leads to a significant avoidance of hospital admissions. A pharmacoeconomic analysis of the results of the CIBIS was conducted for the Federal Republic of Germany, and was restricted to direct costs only. The costs of bisoprolol medication and inpatient treatment of heart failure were considered, the latter forming the major part of costs incurred. Per 1000 patient-years, adjuvant bisoprolol therapy resulted in overall cost savings of Deutschmarks (DM)157,272. Statutory Health Insurance had a net saving of DM186,719 in 1000 patient-years, while patients experienced additional net expenses of DM17,760 over 1000 patient-years. The economic advantage of adjuvant bisoprolol treatment was also borne out in the sensitivity analysis. Adjuvant therapy with bisoprolol was not only clinically beneficial for the patient with heart failure but was also economically advantageous.
Schädlich
P K
PK
InForMed Gesellschaft für interdisziplinäre Forschung und Beratung im Gesundheitswesen mbH, Hamburg, Germany.
Paschen
B
B
Brecht
J G
JG
D000319:Adrenergic beta-Antagonists / Q000191:economics* / Q000627:therapeutic use; D017298:Bisoprolol / Q000191:economics* / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D005858:Germany; D006333:Heart Failure / Q000188:drug therapy / Q000191:economics*; D006801:Humans